WebClinical Trial Program. April 1, 2024 - March 31, 2024. Highlights • The phase II, randomized CYTOSHRINK clinical trial is innovative and unique as it evaluates treatment with SBRT and immunotherapy for metastatic renal cell carcinoma (mRCC) across multiple Canadian sites. • The interrogation of host samples of tumor tissue, blood and stool WebIn contrast, CYTOSHRINK will evaluate PFS in intermediate- or poor-risk patients who are not candidates for cytoreductive nephrectomy .Patients will receive either 30–40 Gy (five …

Faculty – CMHCC

WebIn the latest podcast in the “Clinical Trials in Genitourinary Cancers” series, experts discuss 3 clinical trials testing new treatment options for kidney cancer, muscle-invasive bladder cancer, and metastatic castration-sensitive prostate cancer. ... PROOF 302, and CYTOSHRINK. Language English Brielle.Gregory. In the latest podcast in the ... WebClinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK In the latest podcast in the “Clinical Trials in Genitourinary Cancers” series, experts discuss 3 clinical trials testing new treatments for prostate, bladder, and kidney cancers. chronicle mill towns

bladder cancer Cancer.Net

WebMay 5, 2024 · His academic interests include clinical trial design and translational work for genitourinary malignancies. He is the lead PI for the CYTOSHRINK clinical trial. Dr. Lalani is an active member of the BCC Medical Advisory Committee, participates in the Annual BCC Bladder Cancer Forum and has contributed to the content in many patient guidebooks. WebSep 16, 2024 · SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. chronicle mills